RxSight Research and Development Expenses 2021-2024 | RXST

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

RxSight research and development expenses from 2021 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

RxSight Research and Development Expenses 2021-2024 | RXST

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

RxSight research and development expenses from 2021 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$194.7B
Intuitive Surgical (ISRG)	$191.9B
Alcon (ALC)	$42.1B
Edwards Lifesciences (EW)	$41.4B
IQVIA Holdings (IQV)	$34.7B
IDEXX Laboratories (IDXX)	$34.1B
DexCom (DXCM)	$29.2B
STERIS (STE)	$20.9B
Waters (WAT)	$20.5B
SONOVA HOLDING (SONVY)	$20.3B
Hologic (HOLX)	$18.2B
Fresenius Medical Care AG KGaA (FMS)	$13B
Sysmex ADR (SSMXY)	$12.7B
Globus Medical (GMED)	$11.3B
Penumbra (PEN)	$9.1B
Teleflex (TFX)	$9B
Masimo (MASI)	$8.8B
Glaukos (GKOS)	$8B
PROCEPT BioRobotics (PRCT)	$4.9B
Integer Holdings (ITGR)	$4.5B
Veracyte (VCYT)	$3B
Inari Medical (NARI)	$3B
LivaNova (LIVN)	$2.8B
TransMedics (TMDX)	$2.8B
Nihon Kohden (NHNKY)	$2.3B
Elekta AB (EKTAY)	$2.2B
Tandem Diabetes Care (TNDM)	$1.8B
Integra LifeSciences Holdings (IART)	$1.8B
Alphatec Holdings (ATEC)	$1.4B
Artivion (AORT)	$1.1B